Abstract | INTRODUCTION: METHODS: RESULTS: After 24 weeks of treatment, UACR was slightly decreased in the lobeglitazone group (- 4.3 mg/g creatinine [Cr]) compared to baseline and slightly increased in the pioglitazone group (5.2 mg/g Cr), with no change in the estimated glomerular filtration rate in either group; this difference was not statistically significant (P = 0.476). The incidence of new-onset microalbuminuria (2.4%) and the progression of albuminuria by > 1 stage (2.9%) in the lobeglitazone group were lower than the respective values in the pioglitazone group (6.8 and 6.1%, respectively). Of the patients in the lobeglitazone group, 50% exhibited regression to normoalbuminuria, compared to 39.3% of the patients in the pioglitazone. In subjects in the lobeglitazone group with micro- and macroalbuminuria, UACR tended to be more decreased and HbA1c was more reduced compared to those with normoalbuminuria (P = 0.014). CONCLUSION: TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01106131.
|
Authors | Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park |
Journal | Diabetes therapy : research, treatment and education of diabetes and related disorders
(Diabetes Ther)
Vol. 12
Issue 1
Pg. 171-181
(Jan 2021)
ISSN: 1869-6953 [Print] United States |
PMID | 33099742
(Publication Type: Journal Article)
|